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DETERMINING THE COST OF A BLEEDING-RELATED EPISODE IN PRIMARY 
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OBJECTIVES: Chronic immune thrombocytopenia (ITP) is characterized by low 
platelet counts and an increased risk of bleeding-related episodes (BRE). The 
study purpose was to estimate the cost of BREs in the US. METHODS: A BRE 
includes rescue medication use, a bleeding event, or both. The BRE endpoint was 
tested in two 6-month placebo-controlled trials for romiplostim in adult patients 
with ITP (median baseline platelet counts of 16 x 109/L; 64% received ≥3 
treatments prior to baseline). Results from pooled analyses across studies and 
treatment arms showed that 63% of BREs were mild (outpatient management 
without immunoglobulins), 31% were moderate (outpatient management with 
immunoglobulins), and 6% were severe (inpatient management with 
immunoglobulins). The annual BRE rate per patient was 1.80 for patients with 
platelets ≥50 x 109/L at the time of BRE and 7.33 for patients with platelets <50 x 
109/L. BRE costs were estimated using 2012 Medicare rates for office visits, oral 
steroids, immunoglobulins (IVIg dose of 2 g/kg per episode, and Anti-D dose of 50 
mcg/kg in 25% of non-splenectomized patients), and hospitalization for 
intracranial hemorrhage, gastrointestinal hemorrhage, and coagulation 
disorders. RESULTS: The estimated costs of a mild, moderate, and severe BRE 
were $112, $10,737, and $21,871; with a weighted average BRE cost of $4,703, and 
an average annual cost of $8,465 (platelets ≥50 x 109/L) and $34,473 (platelets <50 
x 109/L). In sensitivity analyses, the cost of immunoglobulins was the most 
important variable; a ±50% change in cost (or dose) resulted in ±41% change in 
the weighted average BRE cost ($2,778 to $6,628). CONCLUSIONS: Bleeding events 
and rescue medications (particularly immunoglobulins) represent a significant 
cost of treatment, particularly in ITP patients with platelet counts lower than <50 
x 109/L.  
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COST IMPACT OF DEPOFOAM BUPIVACAINE FOR THE MANAGEMENT OF POST-
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OBJECTIVES: Clinical trials in soft tissue surgery with Depofoam® bupivacaine 
(DB) have shown that a single injection into the surgical site provides 
postsurgical pain control for up to 72 hours while reducing the need for opioids. 
This study extrapolates via a simplified decision tree the economic impact of DB 
versus bupivacaine HCl (BH) in patients undergoing colectomy and 
cholecystectomy. METHODS: This simple model combined data from a claims 
database analysis with literature. The incidence of opioid use (92%) and risk of 
ICD-9 diagnosis-coded opioid-related adverse events (ORAEs) (16.32%) for the BH 
group were estimated via retrospective analysis of the Premier hospital database. 
The incidence rates of opioid use (68%) and ORAEs (1.86%) in the DB group were 
based on the relative reduction between DB and BH observed in a 
hemorrhoidectomy trial. The excess cost per patient with ORAE ($4,707) was 
estimated from Premier. DB and BH drug acquisition costs, opioid costs 
(including inpatient pharmacy, administration, errors and outpatient pharmacy) 
were literature based. Analyses were conducted in 378 subgroups defined by 
surgery types (colectomy and cholecystectomy) and demographics.  
RESULTS: Compared to BH, the use of DB is projected to result in an increase in 
analgesia drug acquisition cost of $249/patient. This was offset by expected 
reductions in opioids (-$95/patient) and ORAE (-$680/patient) costs, resulting in 
net cost savings of $526/patient overall. DB resulted in modeled costs savings in 
all but one of the 378 subgroups. These ranged from cost savings of 
$1,633/patient in the “open cholecystectomy/admission source trauma” 
subgroup to a cost increase of $28/patient in the “cholecystectomy/age  
18-30” subgroup. CONCLUSIONS: As a result of better pain management and 
reduced opioids usage, the use of DB (v. BH) at the time of 
colectomy/cholecystectomy is modeled to be cost saving overall and in 99.7% of 
subgroups considered.  
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FIRST-LINE USE OF CALCIPOTRIENE/BETAMETHASONE DIPROPIONATE 
COMBINATION PRODUCTS FOR THE TREATMENT OF PLAQUE PSORIASIS IS 
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1Wake Forest University, Winston-Salem, NC, USA, 2LEO Pharma Inc., Parsippany, NJ, USA, 
3Outcomes Inc., Dulles, VA, USA, 4University of Michigan and Outcomes Inc., Dulles, VA, USA  
OBJECTIVES: Calcipotriene/betamethasone dipropionate combination topical 
products are an established treatment for patients with plaque psoriasis. In 
appropriate patients, using the combination products as first-line therapy after 
the psoriasis diagnosis might be beneficial. This study investigated whether such 
use might lower the cost impact on health care budgets. METHODS: A 
retrospective study using Thomson Reuters MarketScan® national claims data 
from 2006-2011 was performed to identify patients who received psoriasis 
medications following a psoriasis diagnosis (ICD-9 code 696.1x). Patients were 
continuously enrolled during 1-year pre- and post-index date periods. The 2 
study cohorts were cohort A (patients treated with calcipotriene/betamethasone 
dipropionate combination products immediately post-diagnosis) and cohort B 
(patients treated with any other topical psoriasis medication immediately post-
diagnosis). The frequency of office visits and total health care costs (includes 
pharmacy costs and costs of inpatient and outpatient services) during the 1-year 
post-index period were assessed. Multiple regression analyses adjusting for 
baseline demographic and clinical covariates, including a proxy for psoriasis 
severity, were performed. RESULTS: In total, 16,977 patients were identified in 
the 2 cohorts based on the topical medication prescribed (cohort A = 7307; cohort 
B = 9670). During the 1-year follow-up period, mean (± SD) total and psoriasis-
related office visits were significantly lower in cohort A (13.36 ± 14.39; 2.79 ± 7.60) 
than cohort B (16.08 ± 16.68; 4.25 ± 10.23) (both P<.001). Mean total health care 
costs were less for cohort A ($7785.80 ± $15,255.60; median = $3411) than cohort B 
($11,757.20 ± $19,747.60; median = $5595.80) (P<.001). In a generalized linear 
model adjusted for baseline covariates, cohort A had significantly lower costs 
than cohort B (β ± SE = 0.041 ± 0.017; P=.02). CONCLUSIONS: First-line treatment 
with calcipotriene/betamethasone dipropionate combination products after 
psoriasis diagnosis was associated with fewer office visits and lower total health 
care costs.  
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OBJECTIVES: Resource evaluation of intravenous patient-controlled analgesia to 
date has focused primarily on nursing or pharmacy staff time. Some have 
quantified IV-PCA related error costs but little data exists on estimated total 
costs from the hospital provider’s perspective. The objective of this study is to 
model IV‐PCA therapy costs in an inpatient, postoperative population. 
METHODS: Cost model data were obtained by 1) survey of 140 hospital pharmacy 
directors (drug, IV-PCA pump-related and non-drug supply costs), 2) Premier 
hospital research database analysis of 7 million surgical discharges from 2008-
2011 (IV-PCA- related complications and cost, and length of stay adjusting for 
demographics, comorbidity and procedures) and 3) by systematic literature 
review (nursing/pharmacy staff time, IV-PCA related errors, delineation of IV-
PCA-related tasks). Sensitivity analyses were conducted. RESULTS: Mean 
duration of IV-PCA in the Premier database per post-surgical inpatient was 
1.7days. The mean cost per day of IV-PCA was $305.37 on day 1, and $264.13 on 
day 2. Individual mean costs per IV-PCA day included pharmacy drug, 
$19.66/day; nursing labor, $38.13 on day 1, and $17.57 on day 2; pharmacy labor, 
$13.17/day; pump cost, $5.24/day; error-related costs, $19.71/day; and non-drug 
disposables, $21.56 on day 1, and $0.88 on day 2. Costs of complications related 
to IV-PCA (DVT, PE, post-op pneumonia occurred in 2.1% of IV-PCA patients vs. 
1.6% of non-IV-PCA patients) added $187.58 per IV-PCA day, with cost adjusted 
for baseline demographics and surgical procedure. In addition to per IV-PCA day 
costs, analyses of Premier data indicate IV-PCA patients had a statistically 
significant extended length of stay adjusting for baseline demographics and 
surgical procedures (mean LOS IV-PCA 4.53 [95% CI 4.41-4.66], LOS non IV-PCA 
4.24 [95% CI 4.12-4.35]). CONCLUSIONS: IV-PCA, while a mainstay of post of post-
operative pain management, is costly. Less resource intensive IV-PCA with fewer 
associated complications could be beneficial to hospitals.  
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OBJECTIVES: To compare medical expenditure and effectiveness of different 
therapies in chronic myeloid leukemia patients who failed in the first-line 
imatinib treatment. METHODS: A structured questionnaire was designed to 
collect the detailed data from 28 clinical experts, including treatment 
alternatives for the patients with chronic myeloid leukemia who failed in first-
line imatinib treatment, and medical service utilization, medical expenditure 
and effectiveness of different therapies (nilotinib, imatinib dose-escalation and 
allo-SCT). RESULTS: The choices of the second-line therapies for the patients 
who failed in the first-line imatinib treatment included nilotinib, imatinib dose-
escalation and allo-SCT. The cytogenetic response of nilotinib was always higher 
than imatinib dose escalation. After 1-1.5 years, the cumulative cytogenetic 
response rate of nilotinib could be as high as 80%, which is significantly higher 
than that of imatinib. The most common adverse effects of nilotinib included 
hematologic toxicities (anemia, thrombocytopenia and neutropenia), 
hyperbilirubinemia, prolongation of QT interval, liver injuries, skin alterations, 
edema, jaundice and gastrointestinal disturbance. In parallel, bone marrow 
suppression is the most frequent toxicities of imatinib dose escalation 
treatment. Other non-hematologic adverse effects were similar, included fluid 
retention, gastrointestinal disturbance, muscular cramp and bone and joint pain. 
The expenditure of nilotinib and dose-escalated imatinib therapies was quite 
similar, and significantly higher than that of first-line imatinib treatment. 
CONCLUSIONS: It is strongly suggested that nilotinib treatment should be 
considered as standard treatment of imatinib-failed patients in China.  
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OBJECTIVES: Systemic Lupus Erythematosus(SLE) is a debilitating illness caused 
by an autoimmune disorder that can affect many organs of the body, including 
skin, joints, kidneys, lungs and the nervous system. Therapy with steroids and 
immunosuppressives can lead to further organ damage. Belimumab is a fully 
human monoclonal antibody that has been found to be effective against SLE in 
trials. The current study assesses the cost-effectiveness of belimumab in Hong 
